Stem cell booster for early liver cirrhosis
Treatments studied
Part of Digestive system clinical trials.
This trial tests whether giving a combination of two medicines (GCSF and Darbepoetin) one time or multiple times can help people with early-stage liver cirrhosis who have started to develop complications. The goal is to see if this treatment can improve liver function and delay the need for a transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 65 years old.
- Your liver disease must be at an early stage of decompensated cirrhosis with a MELD score under 16.
- You cannot have severe fluid buildup in the belly (Grade III ascites) or advanced liver disease (Child C).
- You should not have had variceal bleeding in the past 3 months or have certain infections like spontaneous bacterial peritonitis.
- You must not have liver cancer, kidney injury, or uncontrolled high blood pressure.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests umbilical-cord stem cells to see if they can improve outcomes in people with decompensated (worsening) cirrhosis. You may be considered if your liver disease is moderate to severe (MELD 15–30) and you do not have certain high-risk problems right now.
This trial tests if injecting donated liver cells into the main artery feeding the liver can help people with decompensated cirrhosis. It aims to see if this treatment is safe and might improve liver function.
This trial tests a new cell injection called HCL001 for people with decompensated cirrhosis (advanced liver scarring causing complications). The goal is to see if it's safe and helps improve liver function. It may be an option if you've tried standard treatments and meet specific health criteria.
This study tests whether a combination of two medicines (G-CSF and darbepoetin) given in one or more cycles can improve the body's immune and metabolic health in people with early-stage decompensated cirrhosis (advanced liver disease with mild complications). It compares these treatments with standard medical care.
This trial tests whether infusing stem cells (from a healthy donor) can help people with sudden liver failure that is not getting better with standard medicines and is not caused by viruses. It aims to improve liver function and possibly avoid the need for a transplant.
This trial tests whether injecting special stem cells (called mesenchymal stem cells) can help people with a sudden worsening of chronic liver disease (called acute-on-chronic liver failure) who do not have a virus as the cause. It is for patients who are too sick for standard treatment but who cannot get a liver transplant right away.
Hear when a new Decompensated Cirrhosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.